MP 3.01.550
Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment of Depression and Other Psychiatric/Neurologic Disorders

Related Policies
7.01.20 Vagus Nerve Stimulation
8.01.39 Treatment of Tinnitus

DISCLAIMER/INSTRUCTIONS FOR USE

Medical Policy provides general guidance for applying Blue Cross of Idaho benefit plans (for purposes of Medical Policy, the terms “benefit plan” and “member contract” are used interchangeably). Coverage decisions must reference the member specific benefit plan document. The terms of the member specific benefit plan document may be different than the standard benefit plan upon which this Medical Policy is based. If there is a conflict between a member specific benefit plan and the Blue Cross of Idaho’s standard benefit plan, the member specific benefit plan supersedes this Medical Policy. Any person applying this Medical Policy must identify member eligibility, the member specific benefit plan, and any related policies or guidelines prior to applying this Medical Policy. Blue Cross of Idaho Medical Policies are designed for informational purposes only and are not an authorization, explanation of benefits or a contract. Receipt of benefits is subject to satisfaction of all terms and conditions of the member specific benefit plan coverage. Blue Cross of Idaho reserves the sole discretionary right to modify all its Policies and Guidelines at any time. This Medical Policy does not constitute medical advice.

POLICY

Requests for rTMS must include clinical documentation from the psychiatrist (MD/DO) who has evaluated the patient in person and is recommending this specific treatment. This documentation must include the patient’s current symptoms, treatment history, and rationale for requiring rTMS. Treatments may be administered directly by a qualified psychiatrist or under the direct supervision of the psychiatrist (e.g. physician present in the area and immediately available but does not necessarily personally provide the treatment).

Repetitive transcranial magnetic stimulation (rTMS) and Deep rTMS of the brain may be considered medically necessary as a treatment of major depressive disorder when ALL the following conditions (1-3) have been met:

1. Age 18 years, or older AND
2. Confirmed diagnosis of severe major depressive disorder (single or recurrent) documented by standardized rating scales (e.g. Beck Depression Inventory II, Hamilton Rating Scale for Depression, Geriatric Depression Scale, Major Depression Inventory) that reliably measure depressive symptoms; AND
3. Any one of the following (a, b, or c):
   a. Failure of four (4) trials of psychopharmacologic agents including two (2) different agent classes and two (2) augmentation trials; OR
   b. Inability to tolerate a therapeutic dose of medications as evidenced by four (4) trials of psychopharmacologic agents with distinct side effects; OR
c. There are patient specific barriers to electroconvulsive therapy; AND

4. Failure of a trial of a psychotherapy known to be effective in the treatment of major depressive disorder of an adequate frequency and duration, without significant improvement in depressive symptoms, as documented by standardized rating scales that reliably measure depressive symptoms AND written documentation completed by the patient’s treating therapist confirming poor response to psychotherapy. Submitted documentation by the treating therapist should address patient’s length of treatment, attendance at sessions, overall progress or lack of progress, and identify the type of treatment that occurred. AND

5. Patient has none of the following conditions or contraindications to rTMS:
   a. Seizure disorder or any history or seizure disorder (except those induced by Electroconvulsive Therapy (ECT) or isolated febrile seizures in infancy without subsequent treatment or recurrence); OR
   b. Presence of acute or chronic psychotic symptoms or disorders (e.g., schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode; OR
   c. Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, history of repetitive or severe head trauma, or primary or secondary tumors in the central nervous system; OR
   d. Excessive use of alcohol or illicit substances within the last 30 days.
   e. Presence of an implanted magnetic-sensitive medical device located 30 centimeters or less from the rTMS magnetic coil or other implanted metal items, including but not limited to a cochlear implant, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents.

*Note: If the above conditions are met, 36 acute phase sessions of rTMS may be authorized. A treatment course should not exceed 5 days a week for 6 weeks (total of 30 sessions), followed by a 3-week taper of 3 rTMS treatments in week 1, 2 rTMS treatments the next week, and 1 rTMS treatment in the last week.

Subsequent acute phases rTMS treatments may be considered medically necessary when ALL the following conditions (1-2) have been met:

1. Patient has documented positive response to prior rTMS treatment, as defined by at least a 50% reduction in severity of scores for depression on a standardized rating scale such as the PHQ-9 by the end of acute phase treatment; AND

2. Patient has not received a separate acute phase rTMS treatment within the last 6 months.

Subsequent rTMS is considered investigational for patients who did not respond to a prior episode of rTMS (as defined by not achieving at least 50% reduction in severity of depressions scores on a standardized rating scale by the end of the acute phase treatment, e.g. 36 sessions) and as maintenance treatment for depression (e.g. “booster treatment”).

Repetitive TMS for major depressive disorder that does not meet the criteria listed above is considered investigational.

Repetitive TMS of the brain is considered investigational as a treatment of all other psychiatric/neurologic disorders, including but not limited to bipolar disorder, schizophrenia, obsessive-compulsive disorder, or migraine headaches.
POLICY GUIDELINES

rTMS vs Deep rTMS: There are two main types of rTMS treatment – both fall under the rTMS. rTMS uses a figure 8 coil and the treatment lasts about 40 minutes. Deep rTMS uses an “H” coil and takes approximately 20 minutes.

Repetitive transcranial magnetic stimulation (rTMS) should be performed using a U.S. Food and Drug Administration–cleared device in appropriately selected patients, by physicians who are adequately trained and experienced in the specific techniques used.

The following should be present for the administration of rTMS:

a. An attendant trained in basic cardiac life support and the management of complications such as seizures, as well as the use of the equipment must always be present; and
b. Adequate resuscitation equipment including, for example, suction and oxygen; and
c. The facility must maintain awareness of response times of emergency services (either fire/ambulance or “code team”), which should be available within 5 minutes. These relationships are reviewed at least a 1-year basis and include mock drills.

CODES

There are CPT category I codes for this procedure:

90867: Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management

90868: subsequent delivery and management, per session

90869: subsequent motor threshold re-determination with delivery and management.

Code 90867 is reported once per course of treatment, and codes 90868 and 90869 cannot be reported for the same session.

BENEFIT APPLICATION

BLUECARD/NATIONAL ACCOUNT ISSUES

State or federal mandates (e.g., FEP) may dictate that certain U.S. Food and Drug Administration–approved devices, drugs, or biologics may not be considered investigational, and thus these devices may be assessed only by their medical necessity.

BACKGROUND

TRANSCRANIAL MAGNETIC STIMULATION

Transcranial magnetic stimulation (TMS), introduced in 1985 as a new method of noninvasive stimulation of the brain, involves placement of a small coil over the scalp, passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex. TMS was initially used to investigate nerve conduction; e.g., TMS over the motor cortex will produce a contralateral muscular-evoked potential. The motor threshold, which is the minimum intensity of stimulation required to induce a motor response, is empirically determined for each person by localizing the site on the scalp for optimal stimulation of a hand muscle, then gradually increasing the intensity of stimulation. The stimulation site for treatment of depression is usually 5 cm anterior to the motor stimulation site.
Interest in the use of TMS as a treatment for depression was augmented by the development of a device that could deliver rapid, repetitive stimulation. Imaging studies had shown a decrease in activity of the left dorsolateral prefrontal cortex (DLPFC) in depressed patients, and early studies suggested that high-frequency (e.g., 5-10 Hz) TMS of the left DLPFC had antidepressant effects. Low-frequency (1-2 Hz) stimulation of the right DLPFC has also been investigated. The rationale for low-frequency TMS is inhibition of right frontal cortical activity to correct the interhemispheric imbalance. A combination approach (bilateral stimulation), or deep stimulation with an H1 coil, are also being explored. In contrast to electroconvulsive therapy, TMS does not require general anesthesia and does not generally induce a convulsion.

Repetitive TMS

Repetitive TMS (rTMS) is also being tested as a treatment for a variety of other disorders including alcohol dependence, Alzheimer disease, neuropathic pain, obsessive-compulsive disorder, postpartum depression, Parkinson disease, stroke, posttraumatic stress disorder, panic disorder, epilepsy, dysphagia, Tourette syndrome, schizophrenia, migraine, spinal cord injury, fibromyalgia, and tinnitus. (See evidence review 8.01.39 on rTMS for tinnitus.) In addition to the potential for altering interhemispheric imbalance, it has been proposed that high frequency rTMS may facilitate neuroplasticity.

REGULATORY STATUS

Devices for transcranial stimulation have been cleared for marketing by the U.S. Food and Drug Administration (FDA) for diagnostic uses. The NeoPulse, now known as NeuroStar® TMS, was granted a de novo 510(k) classification by FDA in 2008. A number of devices subsequently received FDA clearance for the treatment of major depressive disorders in adults who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Some devices are listed in Table 1. FDA product code: OBP.

Table 1. rTMS Devices Cleared by FDA for the Treatment of Major Depressive Disorder

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>FDA Clearance No.</th>
<th>FDA Clearance Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NeuroStar® TMS</td>
<td>Neuronetics</td>
<td>DEN070003</td>
<td>2008</td>
</tr>
<tr>
<td>Brainsway™ H-Coil Deep TMS</td>
<td>Brainsway</td>
<td>K122288</td>
<td>2013</td>
</tr>
<tr>
<td>Rapid² Therapy System</td>
<td>Magstim</td>
<td>K162935</td>
<td>2015</td>
</tr>
<tr>
<td>MagVita TMS Therapy System</td>
<td>Tonica Elektronik</td>
<td>K150641</td>
<td>2015</td>
</tr>
<tr>
<td>Neurosoft TMS</td>
<td>TeleEMG</td>
<td>K160309</td>
<td>2016</td>
</tr>
</tbody>
</table>

FDA: Food and Drug Administration; rTMS: repetitive transcranial magnetic stimulation.

In 2013, the Cerena™ TMS device (eNeura Therapeutics) was granted a de novo 510(k) classification by FDA for the acute treatment of pain associated with a migraine headache with aura. Warnings, precautions, and contraindications include the following:

- The device is only intended for patients experiencing the onset of pain associated with a migraine headache with aura.
- The device should not be used:
  - on headaches due to underlying pathology or trauma.
  - for medication overuse headaches.
- The device has not been demonstrated as safe and/or effective:
  - when treating cluster headache or a chronic migraine headache.
  - when treating during the aura phase.
Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment of Depression and Other Psychiatric/Neurologic Disorders

- in relieving the associated symptoms of a migraine (photophobia, phonophobia, and nausea).
- in pregnant women, children under the age of 18, and adults over the age of 65.

The de novo 510(k) review process allows novel products with moderate or low-risk profiles and without predicates, which would ordinarily require premarket approval as a class III device to be down-classified in an expedited manner and brought to market with a special control as a class II device.

In 2014, eNeura Therapeutics received 510(k) marketing clearance for the SpringTMS® for the treatment of migraine headache. The device differs from the predicate Cerena™ TMS device with the addition of an LCD screen, a use authorization feature, lithium battery pack, and smaller size. The stimulation parameters are unchanged. The sTMS Mini (eNeura Therapeutics) received marketing clearance by the FDA in 2016. FDA product code: OKP.

RATIONALE

This evidence review was created in November 2001 and has been updated regularly with searches of the MEDLINE database. This review was informed by a 2009, 2011, and 2013 TEC Assessment.¹³ The most recent literature review was performed through April 25, 2017.

The following summary of the key literature to date focuses on systematic reviews of randomized controlled trials (RCTs). The evidence review on repetitive transcranial magnetic stimulation (rTMS) is divided by indication and by key differences in treatment protocols.

TREATMENT-RESISTANT DEPRESSION

Evaluation of rTMS for treatment-resistant depression (TRD) includes RCTs comparing rTMS with sham as well as evidence when used as a replacement for or adjunct to pharmacotherapy that has not improved depressive symptoms. In addition, evaluation of rTMS in TRD includes the use of rTMS as an alternative to electroconvulsive therapy (ECT). However, some individuals may not want to use ECT due to its requirement for general anesthesia and induction of seizures.

Note that there has been a trend to use rTMS at increased levels of intensity, trains of pulses, total pulses per session, and number of sessions.⁴ Unless otherwise indicated, stimulation was set at 100% to 120% of motor threshold, clinical response was defined as an improvement of 50% or more on the Hamilton Rating Scale for Depression (HAM-D), and remission was considered to be a score of 7 or less on the HAM-D. Refer to the 2009 meta-analysis by Schutter for a summary of study characteristics and stimulation parameters used in trials conducted prior to 2008.⁵

Repetitive TMS for TRD

Systematic Reviews

The Agency for Healthcare Research and Quality published a comparative effectiveness review on nonpharmacologic interventions for TRD in adults in 2011.⁶ Reviewers concluded at that time that comparative clinical research on nonpharmacologic interventions in a TRD population was early in its infancy, and many clinical questions about efficacy and effectiveness remained unanswered. The finding of low strength of evidence was most notable in 2 cases: rTMS compared with ECT resulted in similar clinical outcomes in patients who had failed at least 1 course of antidepressant treatment (based on 2 trials with small sample size), and ECT produced better outcomes than pharmacotherapy. In 2 trials that enrolled patients with probable TRD, ECT produced better outcomes than rTMS. No trials directly compared the likelihood of maintaining remission with nonpharmacologic interventions. The few trials
addressing adverse events, subpopulations, subtypes, and health-related outcomes provided low or insufficient evidence of differences between nonpharmacologic interventions.

Berlim et al reported on a 2013 meta-analysis assessing the effect of rTMS for accelerating and enhancing the clinical response to antidepressants. Data were obtained from 6 double-blind RCTs (total N=392 patients). The response was defined as a 50% or greater reduction in the HAM-D or the Montgomery-Asberg Depression Rating Scale scores. At an average of 2.7 weeks after the start of the combined treatments, response rates were significantly higher with rTMS plus antidepressant treatment (43.3%) compared with sham rTMS (26.8%; odds ratio [OR], 2.50); remission rates did not differ significantly. At the end of the studies (average, 6.8 weeks), response and remission rates were significantly higher with combined high frequency rTMS plus antidepressant treatment compared with sham rTMS (response, 62% vs 46%; OR = -1.9; remission, 53.8% vs 38.6%; OR=2.42).

Another 2013 systematic review by Berlim et al identified 7 RCTs (total N=294 patients) that directly compared rTMS with ECT treatment for patients with depression. After an average of 15.2 sessions of high-frequency rTMS over the left dorsolateral prefrontal cortex (DLPFC), 33.6% of patients were classified as remitters. Fifty-two percent 52% of patients were classified as remitters following an average of 8.2 ECT sessions. The pooled OR was 0.46, indicating a significant difference in outcome favoring ECT.

In 2016, the Health Quality Ontario published a systematic review of left DLPFC rTMS for TRD. Reviewers included 23 RCTs (n=1156 patients) that compared rTMS with sham and 6 RCTs (n=266 patients) that compared rTMS with ECT. In 16 studies, patients received rTMS in addition to antidepressant medication. Seven studies used intensities of less than 100% motor threshold and the definition of remission in the included studies varied (from ≤7 to ≤10 on the HAM-D). Meta-analysis showed a statistically significant improvement in depression scores compared with sham, with a weighted mean difference (WMD) of 2.31 (see Table 1). However, this was smaller than the prespecified clinically important difference of 3.5 points on the HAM-D, and the effect size was small (0.33; 95% confidence interval [CI], 0.17 to 0.5; p<0.001). Subgroup analysis showed a larger and clinically significant treatment effect in the rTMS studies using 20 Hz with shorter train duration compared with other rTMS techniques (WMD=4.96; 95% CI, 1.15 to 8.76; p=0.011). Secondary analyses showed rTMS demonstrated a statistically greater rate of response among 20 studies (pooled relative risk, 1.72; 95% CI, 1.13 to 2.62; p=0.11) as well as statistically greater rate of remission among 13 studies (pooled relative risk, 2.20; 95% CI, 1.44 to 3.38, p<0.001). For the 6 trials that compared rTMS with ECT, the WMD of 5.97 was both statistically and clinically significant in favor of ECT. The relative risk for remission and response rates are shown in Table 1, which while favoring ECT were not statistically significant. Remission and relapse rates at the 6-month follow-up were reported in 2 studies including 40 and 46 subjects, comparing rTMS and ECT. While 1 study reported a slightly higher remission rate for ECT (27.3%) than for rTMS (16.7%), the other study did not find a significant difference between ECT and rTMS for mean depression scores at 3 or 6 months but did note relapses were less frequent for ECT.

Statistical comparisons were either not significant or not available, limiting the interpretation of these findings.

Table 1. Statistical Comparisons for Depression Scores After rTMS

<table>
<thead>
<tr>
<th>Comparison</th>
<th>Favors</th>
<th>WMD (95% CI)</th>
<th>p</th>
<th>RR for Remission (95% CI)</th>
<th>p</th>
<th>RR for Response (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>rTMS vs sham</td>
<td>rTMS</td>
<td>2.31 (1.19 to 3.45)</td>
<td>&lt;0.001</td>
<td>2.20 (1.44 to 3.38)</td>
<td>0.001</td>
<td>1.72 (1.13 to 2.62)</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Original Policy Date: November 2001
Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment of Depression and Other Psychiatric/Neurologic Disorders

<table>
<thead>
<tr>
<th>rTMS vs ECT</th>
<th>ECT</th>
<th>0.02</th>
<th>1.44</th>
<th>0.38</th>
<th>1.72</th>
<th>0.07</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CI: confidence interval; ECT: electroconvulsive therapy; rTMS: repetitive transcranial magnetic stimulation; RR: relative risk; WMD: weighted mean difference.

Randomized Controlled Trials

The largest trial included in the systematic reviews is a 2007 double-blind multicenter (23 study sites) trial with 325 TRD patients randomized to daily sessions (Monday to Friday for 6 weeks) of high-frequency active or sham rTMS of the DLPFC. TRD was defined as failure of at least 1 adequate course of antidepressant treatment. Patients had failed an average of 1.6 treatments in the current episode, with approximately half of the trial population failing to benefit from at least 2 treatments. Intention-to-treat analysis showed a trend favoring the active rTMS group in the primary outcome measure (2 points on the Montgomery-Asberg Depression Rating Scale; p=0.057) and a modest (2-point) but significant improvement over sham treatment on the HAM-D scores. Reviewers reported that, after 6 weeks of treatment, subjects in the active rTMS group were more likely to have achieved remission than the sham controls (14% vs 5%, respectively), although this finding was limited by a loss to follow-up.

The RCT leading to 510(k) clearance of the Brainsway deep TMS system in 2013 was conducted at 20 centers across the United States (n=13), Israel (n=4), Germany (n=2), and Canada (n=1). The trial included 229 patients with major depressive disorder who had not received benefit from 1 to 4 antidepressant trials or were intolerant to at least 2 antidepressant treatments. Using per-protocol analysis, which excluded 31 patients who did not receive adequate TMS treatment and 17 patients who did not meet the inclusion and exclusion criteria, the RCT showed a significant benefit for both response rate (38.4% vs 21.4%) and remission rate (32.6% vs 14.6%). By modified intention-to-treat analysis, which excluded the 17 patients not meeting selection criteria, showed a significant benefit in both response rate (37% vs 22.8%) and remission rate (30.4% vs 15.8%). At the end of the maintenance period (16-week follow-up), the response rate remained significantly improved for deep TMS. Remission rates were not reported. Intention-to-treat analysis found no significant benefit of treatment at 4 or 16 weeks.

Durability of rTMS and Maintenance Therapy

Systematic Reviews

A 2015 meta-analysis examined the durability of the antidepressant effect of high-frequency rTMS on the left DLPFC in the absence of maintenance treatment. Included were 16 double-blind, sham-controlled randomized trials (total N=495 patients). The range of follow-up was 1 to 16 weeks, but most studies only reported follow-up to 2 weeks. The overall effect size was small with a standardized mean difference (SMD; Cohen’s d) of -.48, and the effect sizes were lower in RCTs with 8 to 16 weeks of follow-up (d = -.42) than with 1 to 4 weeks of follow-up (d = -0.54). The effect size was larger when antidepressant medication was initiated concurrently with rTMS (5 RCTs, d = -.56) than when patients were on a stable dose of medication (9 RCTs, d = -.43) or were unmedicated (2 RCTs, d = -.26).

Observational Studies

In 2014, Dunner et al reported 1-year follow-up with maintenance therapy from a large multicenter observational study (42 sites) of rTMS for patients with TRD. A total of 257 patients agreed to participate in the follow-up study of 307 who were initially treated with rTMS. Of them, 205 completed
the 12-month follow-up, and 120 patients had met the Inventory of Depressive Symptoms–Self Report response or remission criteria at the end of treatment. Ninety-three (36.2%) of the 257 patients who enrolled in the follow-up study received additional rTMS (mean, 16.2 sessions). Seventy-five (62.5%) of the 120 patients who met response or remission criteria at the end of the initial treatment phase (including a 2-month taper phase) continued to meet response criteria through 1-year follow-up.

A variety of maintenance schedules are being studied. For example, Richieri et al (2013) used propensity-adjusted analysis of observational data and found that patients who had maintenance rTMS tapered over 20 weeks (from 3 times per week to once a month) had a significantly reduced relapse rate than patients who had no additional treatment (37.8% vs 81.8%). Connolly et al (2012) reported that in the first 100 cases treated at their institution, the response rate was 50.6% and the remission rate was 24.7%. At 6 months after the initial rTMS treatment, 26 (62%) of 42 patients who received tapered maintenance therapy (from 2 sessions per week for the first 3 weeks to monthly) maintained their response. In another study (2010), patients who met criteria for partial response during either a sham-controlled or an open-label phase of a prior study were tapered from rTMS and simultaneously started on maintenance antidepressant monotherapy. During the 24-week follow-up, 10 of 99 patients relapsed, 38 had symptom worsening, and of these 32 (84%) had symptomatic benefit with adjunctive rTMS.

**Section Summary: Treatment-Resistant Depression**

There are a large number of sham-controlled randomized trials and meta-analyses of these RCTs on rTMS for depression. The meta-analyses found a clinical benefit associated with rTMS for TRD, with improved response rates and rates of remission compared with sham. There is some evidence that rTMS, when given in conjunction with the initiation of pharmacologic therapy, improves the response rate compared with pharmacologic therapy alone, while the effect of rTMS is less robust when it is given in combination with a stable dose of antidepressant medication. Meta-analyses also found that the efficacy of rTMS decreases with longer follow-up, though some studies have reported persistent response up to 6 months in some patients. There is limited evidence to compare the effects of these treatments on cognition, although the adverse effects of rTMS appear to be minimal. While the most recent meta-analyses find that the effect of rTMS is smaller than the effect of ECT on TRD, given that rTMS does not require general anesthesia or induction of seizures, some individuals may not want to use ECT, so the balance of incremental benefits and harms associated with rTMS may be a reasonable balance compared with ECT.

**PSYCHIATRIC AND NEUROLOGIC DISORDERS OTHER THAN DEPRESSION**

**Amyotrophic Lateral Sclerosis or Motor Neuron Disease**

A 2013 Cochrane review identified 3 RCTs with a total of 50 participants with amyotrophic lateral sclerosis that compared rTMS with sham TMS. All trials were considered of poor methodologic quality. Heterogeneity prevented pooling of results, and the high rate of attrition further increased the risk of bias. Reviewers concluded that evidence at that time was insufficient to draw conclusions about the efficacy and safety of rTMS in the treatment of amyotrophic lateral sclerosis.

**Chronic Pain**

A 2014 Cochrane review on noninvasive brain stimulation techniques identified 30 RCTs (total N=528 patients) on TMS for chronic pain. There was low to very low quality evidence that low-frequency rTMS or rTMS to the DLPFC is ineffective. Studies on high frequency rTMS to the motor cortex were
heterogeneous, of low quality, and did not demonstrate a significant effect. Due to the low quality of the identified studies, future studies could have a substantial impact on the conclusions.

**Epilepsy**

A 2016 Cochrane review by Chen et al included 7 RCTs on rTMS for epilepsy, 5 of which were completed studies with published data. The total number of participants was 230. All studies had active or placebo controls, and four were double-blinded. However, a meta-analysis could not be conducted due to differences in the design, interventions, and outcomes of the studies. Therefore, a qualitative synthesis was performed. For the outcome of seizure rate, 2 studies showed a significant reduction and 5 studies did not. Of the 4 studies evaluating the mean number of epileptic discharges, 3 studies showed a statistically significant reduction in discharges. Adverse events were uncommon and mild, involving headache, dizziness, and tinnitus. There were no significant changes in medication use.

*Section Summary: Epilepsy*

A number of RCTs have been conducted on the effect of rTMS on epilepsy. All but one were conducted between 2002 and 2008, with the most recent study conducted in 2012. Some trials reported a significant reduction in epileptic discharges, but most did not find a reduction in seizures. The lack of recent primary studies may suggest a loss of interest and support for this intervention following the initial negative results.

**Fibromyalgia**

In 2017, Saltychev and Laimi published a meta-analysis of rTMS for the treatment of patients with fibromyalgia. The meta-analysis included 7 sham-controlled double-blinded controlled trials with low risk of bias. The sample sizes of the trials ranged from 18 to 54. Five of the studies provided high-frequency stimulation to the left primary motor cortex, and the others were to the right or left DLPFC. The number of sessions ranged from 10 to 24, and follow-up ranged from immediately after treatment to 3 months posttreatment. In the pooled analysis, pain severity decreased after the last simulation by 1.2 points (95% CI, -1.7 to -0.8 points) on a 10-point numeric rating scale, while pain severity measured at 1 week to 1 month after the last simulation decreased by 0.7 points (95% CI, -1.0 to -0.3 points). Both were statistically significant but not considered clinically significant, based on a minimal clinically important difference of 1.5 points.

*Section Summary: Fibromyalgia*

A 2017 meta-analysis of 7 sham-controlled randomized trials found that the reduction in pain with rTMS, while statistically significant, was not clinically significant. These results do not support the use of rTMS for the treatment of pain in fibromyalgia. A limitation of the meta-analysis was the relatively small size of the studies and differences in stimulation parameters. In addition, the effect of rTMS on depression, anxiety, sleep, and quality of life was not assessed.

**Migraine Headache**

A pivotal randomized, double-blind, multicenter, sham-controlled trial was performed with the Cerena TMS device to demonstrate the safety and effectiveness for the de novo application. Enrolled in the trial were 201 patients with a history of an aura preceding more than 30% of headaches with moderate or severe headache severity for approximately 90% of migraine attacks. Following a month-long baseline phase to establish the frequency and severity of the migraine, patients were randomized to a treatment phase consisting of 3 treatments or 3 months, whichever occurred first. Patients were instructed to treat their migraine headache during the aura phase and to record their pain severity (0-3), severity of
associated migraine symptoms (photophobia, phonophobia, nausea), presence of vomiting, and use of rescue medications at the time of treatment and at 1, 2, 24, and 48 hours after treatment. The primary end point was the proportion of patients who were pain-free 2 hours after treatment. Of the 201 patients enrolled, 164 recorded at least 1 treatment and 113 recorded at least 1 treatment when there was pain. Post hoc analysis of these 113 patients showed a benefit of the device for the primary end point (37.74% pain free after 2 hours for Cerena vs 16.67% for sham, p=0.018) and for the proportion of subjects who were pain free after 24 hours (33.96% for Cerena vs 10% for sham; p=0.002). Active treatment was not inferior to sham for the proportion of subjects free of photophobia, suggesting that the device does not worsen photophobia. However, the device was not inferior to sham for the proportion of subjects free of nausea and phonophobia.

Section Summary: Migraine Headache

There is little evidence on the TMS devices for the treatment of a migraine headache. The results of the pivotal trial are also limited by the 46% dropout rate and post hoc analysis. According to the Food and Drug Administration labeling, the device has not been demonstrated as safe or effective when treating cluster headache, chronic migraine headache, or migraine headache during the aura phase. The device has not been demonstrated to be as effective in relieving the associated symptoms of migraine (photophobia, phonophobia, nausea). No recent studies have been identified with these devices.

Obsessive-Compulsive Disorder

A 2013 meta-analysis included 10 small RCTs (total N=282 patients) assessing obsessive-compulsive disorder (OCD). Response rates of rTMS augmentation therapy were 35% for active and 13% for sham rTMS. The pooled OR was 3.39, and the number needed to treat was 5. There was no evidence of publication bias. Exploratory subgroup analysis suggested that the most promising stimulation parameters were low frequency rTMS and non-DLPFC regions (i.e., orbitofrontal cortex or supplementary motor area).

A 2016 systematic review by Trevisol et al included 15 RCTs (total N=483 patients) that compared active with sham rTMS for OCD. All studies were sham-controlled and double-blinded. Sample sizes in the trials were small-to-moderate, ranging from 18 to 65 patients (mean sample size, 16.1 patients). Seven studies used low-frequency stimulation and 8 studies used high-frequency stimulation. The cortical regions varied among the studies, targeting the supplementary motor area, orbitofrontal cortex, or left, right, or bilateral DLPFC. The effect size for active stimulation was modest at 0.45 (95% CI, 0.2 to 0.71). The SMD was 2.94 (95% CI, 1.26 to 4.62). Regression did not identify any significant factors. There was no evidence of publication bias from funnel plots.

Section Summary: Obsessive-Compulsive Disorder

The evidence on rTMS for OCD includes a number of small-to-moderate size sham-controlled double-blind randomized trials and meta-analyses of these RCTs. Both meta-analyses found a benefit of rTMS for OCD, but there was substantial variability in the stimulation parameters, including the cortical region that was stimulated and the frequency of stimulation. Additional study in larger numbers of patients is needed to evaluate these parameters.

Panic Disorder

A 2014 Cochrane review identified 2 RCTs (total N=40 patients) that compared low-frequency rTMS with sham rTMS over the right DLPFC. The larger of the 2 studies was a 2013 randomized, double-blind, sham-controlled trial in 21 patients with panic disorder with comorbid major depression. Response
was defined as a 40% or greater decrease on the Panic Disorder Severity Scale and a 50% or greater decrease in HAM-D scores. After 4 weeks of treatment, the response rate for panic was 50% with active rTMS and 8% with sham. The trial had a high risk of attrition bias. The overall quality of evidence for the 2 trials was considered low, and the sample sizes were small, precluding any conclusions about the efficacy of rTMS for panic disorder.

**Parkinson Disease**

A meta-analysis from 2015 included 20 sham-controlled randomized trials (total N=470 patients) evaluating Parkinson disease. Sample sizes ranged from 8 to 102 patients. The total effect size of rTMS on Unified Parkinson’s Disease Rating Scale part III score was 0.46, which is considered a small-to-medium effect size, and the mean change in the Unified Parkinson’s Disease Rating Scale part III score (6.42) was considered a clinically important difference. The greatest effect on motor symptoms was from high-frequency rTMS over the primary motor cortex (SMD=0.77, p<0.001) and low-frequency rTMS over other frontal regions (SMD=0.50, p=0.008). High-frequency rTMS at other frontal regions and low-frequency rTMS over the primary motor cortex did not have a statistically significant benefit. The largest trial (2013) included in the systematic review was an exploratory, multicenter, double-blind trial that randomized 106 patients to 8 weeks of 1-Hz rTMS, 10-Hz rTMS, or sham stimulation over the supplementary motor area. At 9 weeks, all groups showed a similar amount of improvement.

**Section Summary: Parkinson Disease**

A meta-analysis of 20 trials found a medium effect size on motor symptoms in patients with Parkinson disease. However, trials were heterogeneous for the site and frequency of stimulation, and the largest trial found no significant differences between active and sham treatment. It cannot be determined from these results whether the negative results of this trial were due to a lack of effect of rTMS on motor symptoms in general or to stimulation location. Additional study with a larger number of subjects and longer follow-up is needed to determine if high frequency rTMS over the primary motor cortex improves motor symptoms in patients with Parkinson disease.

**Posttraumatic Stress Disorder**

In 2016, Trevizol et al published a systematic review on the efficacy of rTMS for posttraumatic stress disorder (PTSD). Five sham-controlled randomized trials (total N=118 patients) were included. Most trials used stimulation of the right DLPFC, though some delivered rTMS to the left DLPFC or bilaterally. Three trials used high-frequency stimulation while one used low-frequency stimulation and another compared high- with low-frequency stimulation; the percent motor threshold ranged from 80% to 120%. Some trials provided rTMS in combination with a scripted narrative of the traumatic event, and different PTSD scales were used. In a meta-analysis, active rTMS was found to be superior to sham (SMD=0.74; 95% CI, 0.06 to 1.42), although heterogeneity of the trials was high.

**Section Summary: Posttraumatic Stress Disorder**

A meta-analysis of 5 small RCTs (total N=118 patients) found improvement of PTSD with rTMS over the right or left DLPFC. The trials varied by interventions, control conditions, and outcome measures. Additional study in a larger number of patients is needed to confirm an effect of rTMS on PTSD. In addition, the most effective stimulation parameters, the effect of adding a scripted narrative of a traumatic event, and the durability of any effect are unknown.
Schizophrenia

One of the largest areas of TMS research outside of depressive disorders is the treatment of auditory hallucinations in schizophrenia resistant to pharmacotherapy. In 2011, TEC Assessment evaluated TMS as an adjunct treatment for schizophrenia. Five meta-analyses were reviewed, along with RCTs in which measurements were carried out beyond the treatment period. The Assessment concluded that the evidence available at that time was insufficient to demonstrate that TMS is effective in the treatment of schizophrenia.

A 2015 Cochrane review included 41 studies with a total of 1473 participants. Based on very low quality evidence, there was a significant benefit of temporoparietal TMS compared with sham for global state (7 RCTs) and positive symptoms (5 RCTs). The evidence on the cognitive state was equivocal. For prefrontal rTMS compared with sham, the evidence on global state and cognitive state was of very low quality and equivocal. Reviewers concluded that the evidence was insufficient to support or refute the use of TMS to treat symptoms of schizophrenia and, although some evidence suggested that temporoparietal TMS might improve certain symptoms (e.g., auditory hallucinations, positive symptoms of schizophrenia), the results were not robust enough to be unequivocal.

Section Summary: Schizophrenia

The evidence on rTMS for the treatment of auditory hallucinations in schizophrenia consists of small RCTs. Evidence to date has shown small-to-moderate effects on hallucinations when measured at the end of treatment, but suggested the effect is not durable.

Stroke

A number of RCTs and systematic reviews have evaluated rTMS for recovery from stroke. For example, a 2013 Cochrane review included 19 RCTs (total N=588 participants) evaluating the effect of TMS for improving function after stroke. The 2 largest trials (n=183 patients) showed that rTMS was not associated with a significant improvement in Barthel Index scores. Four trials (n=73) found no significant effect on motor function. Subgroup analyses for different stimulation frequencies or durations of illness also did not show a significant benefit of rTMS compared with sham rTMS or no treatment. Reviewers concluded that current evidence did not support the routine use of rTMS for the treatment of stroke.

Hand Function

A 2014 meta-analysis assessed the effect of rTMS on the recovery of hand function and excitability of the motor cortex after stroke. Eight RCTs (total N=273 participants) were selected. The quality of the trials was rated moderate to high, although the size of the studies was small. There was variability in the time since stroke (5 days to 10 years), in the frequency of rTMS applied (1-25 Hz for 1 second to 25 min/d), and the stimulation sites (primary motor cortex or premotor cortex of the unaffected hemisphere). Meta-analysis found a positive effect on finger motor ability (4 studies; n=79 patients; SMD=0.58) and hand function (3 studies; n=74 patients; SMD = -0.82), but no significant change in motor evoked potentials (n=43) or motor threshold (n=62).

Aphasia

A 2015 meta-analysis included 4 RCTs on rTMS over the right pars triangularis for patients (total N=137) with aphasia after stroke. All studies used double-blinding, but therapists were not blinded. Every trial used a different outcome measure, and sample sizes were small (range, 12-40 patients). Meta-analysis showed a medium effect size for naming (p=0.004), a trend for a benefit on repetition (p=0.08), and no
significant benefit for comprehension \((p=0.18)\). Additional study in a larger number of patients would be needed to determine with greater certainty the effect of this treatment on aphasia after stroke.

**Upper Limbs**

In 2016, Graef et al reported a systematic review of rTMS combined with upper-limb training for improving function after stroke.\(^3\)\(^5\) Included were 11 sham-controlled randomized trials with 199 patients that evaluated upper-limb motor and functional status and spasticity; 8 RCTs with sufficient data were included in the meta-analysis. These studies were considered to have a low-to-moderate risk of bias. In the overall analysis, there was no benefit of rTMS on upper-limb function or spasticity \((SMD=0.03; 95\% CI, -0.25 to 0.32)\).

**Section Summary: Stroke**

Evidence consists of a number of RCTs and meta-analyses assessing the effect of rTMS on recovery from stroke. Results are conflicting, and efficacy may depend on the location of the stroke and frequency of the rTMS. Additional study would be needed to determine whether rTMS facilitates standard speech or physical therapy in patients with stroke.

**Substance Abuse and Craving**

Jansen et al reported a 2013 meta-analysis evaluating the effect of rTMS and transcranial direct current stimulation of the DLPFC on substance dependence (alcohol, nicotine, cocaine, marijuana) or craving for high palatable food.\(^3\)\(^6\) Seventeen double-blind, sham-controlled controlled trials that used high-frequency stimulation were included in the analysis. Thirteen studies stimulated the left DLPFC and 7 studies stimulated the right DLPFC or both sides. Twelve of the studies gave only 1 or 2 sessions. The standardized effect size was 0.476 \((95\% CI, 0.316 to 0.636)\), indicating a medium effect size for active stimulation over sham for a reduction in craving. However, the studies were small \((range, 9-48 patients)\) and there was significant heterogeneity in selected studies. No significant differences were found in the effectiveness of rTMS vs transcranial direct current stimulation, the different substances, or the side of stimulation, although this analysis might have been biased by the number of studies for each condition.

**Section Summary: Substance Abuse and Craving**

A number of sham-controlled randomized trials and a meta-analysis of these have found a medium effect size of rTMS for reduction of substance or food craving. Most studies examined acute craving after 1 or 2 rTMS sessions, and there is limited evidence on longer term efficacy of this treatment approach.

**SUMMARY OF EVIDENCE**

For individuals who have TRD who receive repetitive transcranial magnetic stimulation (rTMS), the evidence includes a large number of sham-controlled randomized controlled trials (RCTs) and meta-analyses of these trials. Relevant outcomes are symptoms, functional outcomes, and quality of life. The meta-analyses find a clinical benefit associated with rTMS for TRD with improved response rates and rates of remission compared with sham. The most recent meta-analyses have concluded that the effect of rTMS, on average depression scores, is smaller than the effect of electroconvulsive therapy (ECT) on TRD and that the mean improvement in depression scores with rTMS did not reach the minimal clinically important difference; however, clinically meaningful improvements were noted in a subgroup of studies using higher frequency pulses. One potential area of benefit for rTMS is in accelerating or enhancing the response to antidepressant medications, and there is some evidence that rTMS, when given in conjunction with the initiation of pharmacologic therapy, improves the response rate compared with
pharmacologic therapy alone. The effect of rTMS appears to be less robust when it is given in combination with a stable dose of antidepressant medication. Meta-analyses have also found that the efficacy of rTMS decreases with longer follow-up, though some studies have reported persistent response up to 6 months in some patients. There is limited evidence to compare the effects of these treatments on cognition, although the adverse events of rTMS appear to be minimal. While the most recent meta-analyses found that the effect of rTMS is smaller than the effect of ECT on TRD, because rTMS does not require general anesthesia or induce seizures, some individuals may decline ECT so the balance of incremental benefits and harms associated with rTMS may be a reasonable balance compared with ECT. Based on the short-term benefit observed in RCTs and the lack of alternative treatments, aside from ECT in patients with TRD, rTMS may be considered a treatment option in patients with TRD who meet specific criteria. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have psychiatric or neurologic disorders other than depression (e.g., amyotrophic lateral sclerosis, chronic pain, epilepsy, fibromyalgia, migraine headache, obsessive-compulsive disorder, panic disorder, Parkinson disease, posttraumatic stress disorder, schizophrenia, stroke, substance abuse and craving) who receive rTMS, the evidence includes numerous small RCTs and meta-analyses of these RCTs. Relevant outcomes are symptoms, functional outcomes, and quality of life. The trials included in the meta-analyses are typically small and of low methodologic quality. In addition, stimulation parameters have not been established, and trial results are heterogeneous. There are no large, high-quality trials for any of these conditions demonstrating efficacy. A demonstration of the durability of any treatment effects would also be needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

SUPPLEMENTAL INFORMATION

CLINICAL INPUT FROM PHYSICIAN SPECIALTY SOCIETIES AND ACADEMIC MEDICAL CENTERS

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received from 1 physician specialty society and 3 academic medical centers while this policy was under review in 2014. Reviewers considered repetitive transcranial magnetic stimulation to be medically necessary for treatment-resistant depression. Input agreed with the proposed criteria for treatment of treatment-resistant depression with repetitive transcranial magnetic stimulation, as included in the policy statement.

PRACTICE GUIDELINES AND POSITION STATEMENTS

American Psychiatric Association

The American Psychiatric Association’s 2010 practice guidelines (reaffirmed in 2015) for the treatment of patients with major depressive disorder have indicated that treatment in the acute phase should be aimed at inducing remission of the major depressive episode and achieving a full return to the patient’s baseline level of functioning (recommended with substantial clinical confidence). Acute phase treatment may include pharmacotherapy, depression-focused psychotherapy, the combination of medications and psychotherapy, or other somatic therapies such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or light therapy. The Association stated that a number of strategies are available when a change in the treatment plan seems necessary, such as transdermal
selegiline, a relatively selective monoamine oxidase B inhibitor with fewer dietary and medication restrictions, or transcranial magnetic stimulation could also be considered (recommended with moderate clinical confidence).

The Association’s guidelines on the treatment of patients with obsessive-compulsive disorder (2007, reaffirmed in 2012) have indicated that “findings of the four published trials of repetitive TMS (rTMS) are inconsistent, perhaps because the studies differed in design, stimulation sites, duration, and stimulation parameters. The available results and the technique’s non-invasiveness and good tolerability should encourage future research, but the need for daily treatment may limit the use of TMS in practice.”

International Federation of Clinical Neurophysiology

A group of European experts was commissioned to establish evidence-based guidelines on the therapeutic use of rTMS. Their 2014 guidelines included evidence published up until March 2014. For most indications, there was an absence of sufficient evidence, and the committee could provide no recommendation. Indications that had a recommendation of a definite effect were neuropathic pain and depression. Indications that had a recommendation for a possible or probable effect included complex regional pain syndrome, Parkinson disease, motor stroke, hemispatial neglect, epilepsy, tinnitus, anxiety disorders, auditory hallucinations, a negative symptom of schizophrenia, as well as addiction and craving.

American Academy of Child and Adolescent Psychiatry

In 2013, the American Academy of Child and Adolescent Psychiatry published practice parameters on the assessment and treatment of children and adolescents with tic disorders. The Academy did not recommend rTMS, citing the limited evidence on the safety, ethics, and long-term impact on development.

National Institute for Health and Care Excellence

In 2015, the National Institute for Health and Care Excellence provided revised guidance, stating that evidence on the short-term efficacy of rTMS for depression is adequate, although the clinical response is variable and some patients may not benefit.

In 2014, the Institute provided guidance on the use of rTMS for treating and preventing migraine. The guidance stated that evidence on the efficacy of TMS for the treatment of a migraine is limited in quantity and for the prevention of a migraine is limited in both quality and quantity. Evidence on its safety in the short and medium term is adequate, but there is uncertainty about the safety of long-term or frequent use of TMS.

American Academy of Neurology

The American Academy of Neurology issued practice guidelines in 2006 on the evaluation and treatment of depression, psychosis, and dementia in Parkinson disease. The guidelines found the evidence insufficient to support or refute the efficacy of TMS or ECT in the treatment of depression associated with Parkinson disease (level U; data inadequate or conflicting given current knowledge, treatment is unproven).

Canadian Network for Mood and Anxiety Treatments

The Canadian Network for Mood and Anxiety Treatments updated its clinical guidelines on neurostimulation therapies for the management of major depressive disorder in adults in 2009.
evidence reviewed supported ECT as a first-line treatment under specific circumstances; when used in patients who have failed to respond to one or more adequate antidepressant medication trials, ECT response rates have been estimated to be 50% to 60%. The guidelines considered rTMS to be a safe and well-tolerated treatment, with no evidence of cognitive impairment. Based on the 2008 meta-analysis by Lam et al,\textsuperscript{45} response (25%) and remission (17%) rates were found to be greater than sham but lower than for other interventions for treatment-resistant depression, leading to a recommendation for rTMS as a second-line treatment. The guidelines indicated that there was a major gap in the evidence base regarding maintenance rTMS, because only 1 open-label case series was identified.

**U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS**

Not applicable.

**MEDICARE NATIONAL COVERAGE**

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

**ONGOING AND UNPUBLISHED CLINICAL TRIALS**

A search of ClinicalTrials.gov in May 2017 identified over 300 ongoing trials on rTMS.

**ESSENTIAL HEALTH BENEFITS**

The Affordable Care Act (ACA) requires fully insured non-grandfathered individual and small group benefit plans to provide coverage for ten categories of Essential Health Benefits (“EHBs”), whether the benefit plans are offered through an Exchange or not. States can define EHBs for their respective state.

States vary on how they define the term small group. In Idaho, a small group employer is defined as an employer with at least two but no more than fifty eligible employees on the first day of the plan or contract year, the majority of whom are employed in Idaho. Large group employers, whether they are self-funded or fully insured, are not required to offer EHBs, but may voluntary offer them.

The Affordable Care Act requires any benefit plan offering EHBs to remove all dollar limits for EHBs.

**REFERENCES**


8. Berlim MT, Van den Eynde F, Daskalakis ZJ. Efficacy and acceptability of high frequency repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for major depression: a systematic review and meta-analysis of randomized trials. Depress Anxiety. Jul 2013;30(7):614-623. PMID 23349112


CODES

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>90867</td>
<td>Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management</td>
</tr>
<tr>
<td></td>
<td>90868</td>
<td>Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session</td>
</tr>
<tr>
<td></td>
<td>90869</td>
<td>Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management</td>
</tr>
</tbody>
</table>

| ICD-10-CM | F32.0-F32.9 | Major depressive disorder, single episode, code range |
| ICD-10-CM | F33.0-F33.9 | Major depressive disorder, recurrent, code range |

| ICD-10-PCS | | ICD-10-PCS codes are only used for inpatient services. There is no specific ICD-10-PCS code for this procedure |

| Type of Service | Medicine |
| Place of Service | Outpatient |

POLICY HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/12/14</td>
<td>Replace policy</td>
<td>Policy updated with literature review through December 11, 2013; references 4, 16, 26, and 59-63 added and reordered; clinical input reviewed; transcranial</td>
</tr>
</tbody>
</table>
### Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment of Depression and Other Psychiatric/Neurologic Disorders

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/11/14</td>
<td>Replace policy</td>
<td>Policy updated with literature review through October 30, 2014; references 9, 15, 17, 25, 27, 36, 48, 52-53, and 55 added and some references removed; policy statements unchanged.</td>
</tr>
<tr>
<td>08/26/15</td>
<td>Replace policy</td>
<td>Policy statement updated to include statement: Requests for rTMS must include clinical documentation from a psychiatrist (MD/DO) who has evaluated the patient in person and is recommending this specific treatment. This documentation must include the patient's current symptoms, treatment history and rationale for requiring rTMS. Also, added to bullet #3 clinical documentation will be required.</td>
</tr>
<tr>
<td>11/06/15</td>
<td>Update only</td>
<td>Added to policy statement: Treatments must be administered by a board-certified psychiatrist who has specific training in this therapy; Repetitive transcranial magnetic stimulation (rTMS) of the brain is considered an alternative to traditional treatments, when such treatments have failed for clarification.</td>
</tr>
<tr>
<td>12/10/15</td>
<td>Replace policy</td>
<td>Policy updated with literature review through November 9, 2015; references 17, 36, 43, 46, and 48 added. Policy statements unchanged.</td>
</tr>
<tr>
<td>01/18/17</td>
<td>Replace policy</td>
<td>Blue Cross of Idaho annual review; no change to policy.</td>
</tr>
<tr>
<td>01/30/18</td>
<td>Replace policy</td>
<td>Blue Cross of Idaho adopted changes as noted, with changes to policy statement. “Board certified” psychiatrist requirement removed and changed to psychiatrist “who has been certified in this treatment modality.” Policy updated with literature review through April 25, 2017; references 9, 19, 21, 24, 29, and 35 added.</td>
</tr>
<tr>
<td>04/30/18</td>
<td>Update only</td>
<td>Medical policy renumbered from 2.01.50 to 2.01.550.</td>
</tr>
<tr>
<td>11/15/18</td>
<td>Replace policy</td>
<td>Blue Cross of Idaho annual review; no change to policy.</td>
</tr>
<tr>
<td>06/20/19</td>
<td>Replace policy</td>
<td>Policy number changed from 2.01.550 to 3.01.550. Policy moved from medicine section to mental health section. Blue Cross of Idaho adopted changes as noted, effective 09/20/2019. Addition of statement “administration under the supervision of a qualified physician”. Expansion of the qualifications for rTMS. Criteria listed in the Guidelines was moved to the Policy statement.</td>
</tr>
<tr>
<td>10/24/19</td>
<td>Replace policy</td>
<td>Blue Cross of Idaho adopted changes as noted, effective 10/24/2019. Added clarification regarding rTMS therapy and Deep rTMS therapy. &quot;Supervising physician&quot; updated to state &quot;supervising psychiatrist&quot;.</td>
</tr>
</tbody>
</table>